List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2757072/publications.pdf Version: 2024-02-01

		18436	14156
317	19,778	62	128
papers	citations	h-index	g-index
351	351	351	23416
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 557-582.	2.5	2,393
2	Small-Airway Obstruction and Emphysema in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2011, 365, 1567-1575.	13.9	951
3	The Relationship Between Reduced Lung Function and Cardiovascular Mortality. Chest, 2005, 127, 1952-1959.	0.4	776
4	ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. European Respiratory Journal, 2020, 55, 2000688.	3.1	668
5	Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. European Respiratory Journal, 2017, 49, 1700214.	3.1	536
6	The Lung Tissue Microbiome in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2012, 185, 1073-1080.	2.5	469
7	Chronic Obstructive Pulmonary Disease as a Risk Factor for Cardiovascular Morbidity and Mortality. Proceedings of the American Thoracic Society, 2005, 2, 8-11.	3.5	449
8	Canadian Thoracic Society Recommendations for Management of Chronic Obstructive Pulmonary Disease – 2007 Update. Canadian Respiratory Journal, 2007, 14, 5B-32B.	0.8	415
9	New genetic signals for lung function highlight pathways and chronic obstructive pulmonary disease associations across multiple ancestries. Nature Genetics, 2019, 51, 481-493.	9.4	350
10	Informe 2017 de la Iniciativa Global para el Diagnóstico, Tratamiento y Prevención de la Enfermedad Pulmonar Obstructiva Crónica: Resumen Ejecutivo de GOLD. Archivos De Bronconeumologia, 2017, 53, 128-149.	0.4	312
11	Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. Respirology, 2017, 22, 575-601.	1.3	299
12	What is asthmaâ^'COPD overlap syndrome? Towards a consensus definition from a round table discussion. European Respiratory Journal, 2016, 48, 664-673.	3.1	287
13	Lung eQTLs to Help Reveal the Molecular Underpinnings of Asthma. PLoS Genetics, 2012, 8, e1003029.	1.5	261
14	Genome-wide association analyses for lung function and chronic obstructive pulmonary disease identify new loci and potential druggable targets. Nature Genetics, 2017, 49, 416-425.	9.4	257
15	Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax, 2005, 60, 992-997.	2.7	253
16	Prevalence of Pulmonary Embolism in Acute Exacerbations of COPD. Chest, 2009, 135, 786-793.	0.4	252
17	COVID-19 and COPD. European Respiratory Journal, 2020, 56, 2002108.	3.1	234
18	Genetic variants associated with susceptibility to idiopathic pulmonary fibrosis in people of European ancestry: a genome-wide association study. Lancet Respiratory Medicine,the, 2017, 5, 869-880.	5.2	233

#	Article	IF	CITATIONS
19	Contemporary Management of Acute Exacerbations of COPD. Chest, 2008, 133, 756-766.	0.4	217
20	Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 564-574.	2.5	208
21	Smooth Muscle Cells Contribute the Majority of Foam Cells in ApoE (Apolipoprotein E)-Deficient Mouse Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 876-887.	1.1	199
22	The Effects of Fluticasone with or without Salmeterol on Systemic Biomarkers of Inflammation in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2008, 177, 1207-1214.	2.5	195
23	Host Response to the Lung Microbiome in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 438-445.	2.5	195
24	Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet, The, 2009, 374, 712-719.	6.3	188
25	Moderate-to-severe asthma in individuals of European ancestry: a genome-wide association study. Lancet Respiratory Medicine,the, 2019, 7, 20-34.	5.2	183
26	Benralizumab for the Prevention of COPD Exacerbations. New England Journal of Medicine, 2019, 381, 1023-1034.	13.9	180
27	Underdiagnosis and Overdiagnosis of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1130-1139.	2.5	179
28	Characteristics of COPD in never-smokers and ever-smokers in the general population: results from the CanCOLD study. Thorax, 2015, 70, 822-829.	2.7	178
29	Female smokers beyond the perimenopausal period are at increased risk of chronic obstructive pulmonary disease: a systematic review and meta-analysis. Respiratory Research, 2006, 7, 52.	1.4	174
30	COPD and the risk of poor outcomes in COVID-19: A systematic review and meta-analysis. EClinicalMedicine, 2021, 33, 100789.	3.2	160
31	The Obesity Paradox in Patients With Peripheral Arterial Disease. Chest, 2008, 134, 925-930.	0.4	154
32	Marijuana and chronic obstructive lung disease: a population-based study. Cmaj, 2009, 180, 814-820.	0.9	152
33	The role of female hormones on lung function in chronic lung diseases. BMC Women's Health, 2011, 11, 24.	0.8	143
34	Changes in the Bacterial Microbiota in Gut, Blood, and Lungs following Acute LPS Instillation into Mice Lungs. PLoS ONE, 2014, 9, e111228.	1.1	141
35	Mortality prediction in chronic obstructive pulmonary disease comparing the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respiratory Medicine,the, 2015, 3, 443-450.	5.2	125
36	Canadian Cohort Obstructive Lung Disease (CanCOLD): Fulfilling the Need for Longitudinal Observational Studies in COPD. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 125-132.	0.7	122

#	Article	IF	CITATIONS
37	Sex Differences in Airway Remodeling in a Mouse Model of Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 825-834.	2.5	122
38	Asthma-COPD overlap syndrome: pathogenesis, clinical features, and therapeutic targets. BMJ: British Medical Journal, 2017, 358, j3772.	2.4	119
39	The Cost-Effectiveness of High-Risk Lung Cancer Screening and Drivers of Program Efficiency. Journal of Thoracic Oncology, 2017, 12, 1210-1222.	0.5	112
40	Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is There a Pulmonary Vascular Phenotype?. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 1000-1011.	2.5	111
41	Undiagnosed Chronic Obstructive Pulmonary Disease Contributes to the Burden of Health Care Use. Data from the CanCOLD Study. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 285-298.	2.5	110
42	Sixteen new lung function signals identified through 1000 Genomes Project reference panel imputation. Nature Communications, 2015, 6, 8658.	5.8	108
43	Chronic obstructive pulmonary disease: a novel risk factor for cardiovascular disease. Canadian Journal of Physiology and Pharmacology, 2005, 83, 8-13.	0.7	99
44	The Projected Epidemic of Chronic Obstructive Pulmonary Disease Hospitalizations over the Next 15 Years. A Population-based Perspective. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 287-291.	2.5	98
45	Sputum Microbiome Is Associated with 1-Year Mortality after Chronic Obstructive Pulmonary Disease Hospitalizations. American Journal of Respiratory and Critical Care Medicine, 2019, 199, 1205-1213.	2.5	95
46	Serum PARC/CCL-18 Concentrations and Health Outcomes in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2011, 183, 1187-1192.	2.5	93
47	Understanding the Biological Differences in Susceptibility to Chronic Obstructive Pulmonary Disease between Men and Women. Proceedings of the American Thoracic Society, 2007, 4, 671-674.	3.5	90
48	Systematic Review of Blood Biomarkers in Cystic Fibrosis Pulmonary Exacerbations. Chest, 2013, 144, 1659-1670.	0.4	89
49	A large lung gene expression study identifying fibulin-5 as a novel player in tissue repair in COPD. Thorax, 2015, 70, 21-32.	2.7	89
50	Epidemic of Lung Cancer in Patients With HIV Infection. Chest, 2013, 143, 305-314.	0.4	87
51	American Thoracic Society/National Heart, Lung, and Blood Institute Asthma–Chronic Obstructive Pulmonary Disease Overlap Workshop Report. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 375-381.	2.5	86
52	Multiethnic meta-analysis identifies ancestry-specific and cross-ancestry loci for pulmonary function. Nature Communications, 2018, 9, 2976.	5.8	85
53	Pulmonary Rehabilitation in a Post-COVID-19 World: Telerehabilitation as a New Standard in Patients with COPD. International Journal of COPD, 2021, Volume 16, 379-391.	0.9	84
54	A Systematic Review of Diagnostic Biomarkers of COPD Exacerbation. PLoS ONE, 2016, 11, e0158843.	1.1	81

#	Article	IF	CITATIONS
55	Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. European Respiratory Journal, 2020, 55, 2000351.	3.1	81
56	The Relationship between Telomere Length and Mortality in Chronic Obstructive Pulmonary Disease (COPD). PLoS ONE, 2012, 7, e35567.	1.1	80
57	Prioritization of candidate causal genes for asthma in susceptibility loci derived from UK Biobank. Communications Biology, 2021, 4, 700.	2.0	77
58	Diagnostic Instability and Reversals of Chronic Obstructive Pulmonary Disease Diagnosis in Individuals with Mild to Moderate Airflow Obstruction. American Journal of Respiratory and Critical Care Medicine, 2017, 196, 306-314.	2.5	76
59	Pro–Surfactant Protein B As a Biomarker for Lung Cancer Prediction. Journal of Clinical Oncology, 2013, 31, 4536-4543.	0.8	73
60	BMI is associated with FEV1 decline in chronic obstructive pulmonary disease: a meta-analysis of clinical trials. Respiratory Research, 2019, 20, 236.	1.4	72
61	The Acute COPD Exacerbation Prediction Tool (ACCEPT): a modelling study. Lancet Respiratory Medicine,the, 2020, 8, 1013-1021.	5.2	72
62	Integrative Approach to Quality Assessment of Medical Journals Using Impact Factor, Eigenfactor, and Article Influence Scores. PLoS ONE, 2010, 5, e10204.	1.1	70
63	Exacerbation-like respiratory symptoms in individuals without chronic obstructive pulmonary disease: results from a population-based study. Thorax, 2014, 69, 709-717.	2.7	70
64	SARS-CoV-2 receptor ACE2 gene expression and RAAS inhibitors. Lancet Respiratory Medicine,the, 2020, 8, e50-e51.	5.2	68
65	COVID-19 and nicotine as a mediator of ACE-2. European Respiratory Journal, 2020, 55, 2001261.	3.1	67
66	Refining Susceptibility Loci of Chronic Obstructive Pulmonary Disease with Lung eqtls. PLoS ONE, 2013, 8, e70220.	1.1	66
67	Molecular mechanisms underlying variations in lung function: a systems genetics analysis. Lancet Respiratory Medicine,the, 2015, 3, 782-795.	5.2	66
68	Effects of Nocturnal Noninvasive Mechanical Ventilation on Heart Rate Variability of Patients With Advanced COPD. Chest, 2007, 131, 156-163.	0.4	65
69	Estradiol Increases Mucus Synthesis in Bronchial Epithelial Cells. PLoS ONE, 2014, 9, e100633.	1.1	63
70	Findings on Thoracic Computed Tomography Scans and Respiratory Outcomes in Persons with and without Chronic Obstructive Pulmonary Disease: A Population-Based Cohort Study. PLoS ONE, 2016, 11, e0166745.	1.1	63
71	Biomarkers in Chronic Obstructive Pulmonary Disease. Proceedings of the American Thoracic Society, 2009, 6, 543-545.	3.5	62
72	A Comparison between Droplet Digital and Quantitative PCR in the Analysis of Bacterial 16S Load in Lung Tissue Samples from Control and COPD GOLD 2. PLoS ONE, 2014, 9, e110351.	1.1	57

#	Article	IF	CITATIONS
73	IL-22 and its receptors are increased in human and experimental COPD and contribute to pathogenesis. European Respiratory Journal, 2019, 54, 1800174.	3.1	54
74	A simple algorithm for the identification of clinical COPD phenotypes. European Respiratory Journal, 2017, 50, 1701034.	3.1	53
75	Towards large-scale case-finding: training and validation of residual networks for detection of chronic obstructive pulmonary disease using low-dose CT. The Lancet Digital Health, 2020, 2, e259-e267.	5.9	53
76	The Complex Relationship of Serum Adiponectin to COPD Outcomes. Chest, 2012, 142, 893-899.	0.4	51
77	Biomarker Development for Chronic Obstructive Pulmonary Disease. From Discovery to Clinical Implementation. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1162-1170.	2.5	51
78	Arterial carbon dioxide tension on admission as a marker of in-hospital mortality in community-acquired pneumonia. American Journal of Medicine, 2005, 118, 145-150.	0.6	50
79	Current Status and Future Opportunities in Lung Precision Medicine Research with a Focus on Biomarkers. An American Thoracic Society/National Heart, Lung, and Blood Institute Research Statement. American Journal of Respiratory and Critical Care Medicine, 2018, 198, e116-e136.	2.5	49
80	Smoking, ACE-2 and COVID-19: ongoing controversies. European Respiratory Journal, 2020, 56, 2001759.	3.1	49
81	Biomarkers in COPD. Clinics in Chest Medicine, 2014, 35, 131-141.	0.8	48
82	Corticosteroids and adrenoceptor agonists: The compliments for combination therapy in chronic airways diseases. European Journal of Pharmacology, 2006, 533, 28-35.	1.7	46
83	Update on Asthma–COPD Overlap (ACO): A Narrative Review. International Journal of COPD, 2021, Volume 16, 1783-1799.	0.9	46
84	Surfactant protein D is a causal risk factor for COPD: results of Mendelian randomisation. European Respiratory Journal, 2017, 50, 1700657.	3.1	45
85	Genome-wide association study on the FEV 1 /FVC ratio in never-smokers identifies HHIP and FAM13A. Journal of Allergy and Clinical Immunology, 2017, 139, 533-540.	1.5	45
86	Identification and definition of asthma–COPD overlap: The CanCOLD study. Respirology, 2020, 25, 836-849.	1.3	45
87	Airway hyperresponsiveness in chronic obstructive pulmonary disease: AÂmarker of asthma-chronic obstructive pulmonary disease overlap syndrome?. Journal of Allergy and Clinical Immunology, 2016, 138, 1571-1579.e10.	1.5	44
88	Excess economic burden of comorbidities in COPD: a 15-year population-based study. European Respiratory Journal, 2017, 50, 1700393.	3.1	44
89	Effects of Inhaled Corticosteroid/Long-Acting β ₂ -Agonist Combination on the Airway Microbiome of Patients with Chronic Obstructive Pulmonary Disease: A Randomized Controlled Clinical Trial (DISARM). American Journal of Respiratory and Critical Care Medicine, 2021, 204, 1143-1152.	2.5	44
90	Serial blood eosinophils and clinical outcome in patients with chronic obstructive pulmonary disease. Respiratory Research, 2018, 19, 134.	1.4	43

#	Article	IF	CITATIONS
91	Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, 3, 210-232.	0.2	43
92	Effects of increased primary care access on process of care and health outcomes among patients with asthma who frequent emergency departments. American Journal of Medicine, 2004, 117, 479-483.	0.6	41
93	Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a randomised controlled trial. European Respiratory Journal, 2021, 58, 2100130.	3.1	39
94	Progression of Airway Dysplasia and C-Reactive Protein in Smokers at High Risk of Lung Cancer. American Journal of Respiratory and Critical Care Medicine, 2006, 173, 535-539.	2.5	38
95	Pathobiologic Mechanisms of Chronic Obstructive Pulmonary Disease. Medical Clinics of North America, 2012, 96, 681-698.	1.1	38
96	Individualized prediction of lung-function decline in chronic obstructive pulmonary disease. Cmaj, 2016, 188, 1004-1011.	0.9	38
97	Discovery of novel plasma protein biomarkers to predict imminent cystic fibrosis pulmonary exacerbations using multiple reaction monitoring mass spectrometry. Thorax, 2016, 71, 216-222.	2.7	38
98	Impact of cancers and cardiovascular diseases in chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine, 2008, 14, 115-121.	1.2	37
99	Leveraging lung tissue transcriptome to uncover candidate causal genes in COPD genetic associations. Human Molecular Genetics, 2018, 27, 1819-1829.	1.4	37
100	Introduction to precision medicine in COPD. European Respiratory Journal, 2019, 53, 1802460.	3.1	37
101	COPD: Do Imaging Measurements of Emphysema and Airway Disease Explain Symptoms and Exercise Capacity?. Radiology, 2015, 277, 872-880.	3.6	36
102	Biomarker Development in COPD. Chest, 2017, 151, 455-467.	0.4	36
103	Lung tissue gene-expression signature for the ageing lung in COPD. Thorax, 2018, 73, 609-617.	2.7	36
104	Multi-omics highlights ABO plasma protein as a causal risk factor for COVID-19. Human Genetics, 2021, 140, 969-979.	1.8	36
105	The impact of lockdown timing on COVID-19 transmission across US counties. EClinicalMedicine, 2021, 38, 101035.	3.2	36
106	Serum Surfactant Protein D during Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Disease Markers, 2009, 27, 287-294.	0.6	34
107	Genome-wide interaction study of gene-by-occupational exposure and effects on FEV1 levels. Journal of Allergy and Clinical Immunology, 2015, 136, 1664-1672.e14.	1.5	34
108	Lung exposure to lipopolysaccharide causes atherosclerotic plaque destabilisation. European Respiratory Journal, 2016, 48, 205-215.	3.1	34

#	Article	IF	CITATIONS
109	Sex-Related Differences in Pulmonary Function following 6 Months of Cigarette Exposure: Implications for Sexual Dimorphism in Mild COPD. PLoS ONE, 2016, 11, e0164835.	1.1	34
110	Can age and sex explain the variation in COPD rates across large urban cities? A population study in Canada. International Journal of Tuberculosis and Lung Disease, 2011, 15, 1691-1698.	0.6	33
111	Future Impact of Various Interventions on the Burden of COPD in Canada: A Dynamic Population Model. PLoS ONE, 2012, 7, e46746.	1.1	32
112	The effects of marijuana smoking on lung function in older people. European Respiratory Journal, 2019, 54, 1900826.	3.1	32
113	Association between COPD exacerbations and lung function decline during maintenance therapy. Thorax, 2020, 75, 744-753.	2.7	32
114	Forced expiratory volume in 1 second and physical activity in the general population. American Journal of Medicine, 2004, 117, 270-273.	0.6	31
115	Statins Reduce Ambient Particulate Matter-Induced Lung Inflammation by Promoting the Clearance of Particulate Matter &It 10 μm From Lung Tissues. Chest, 2013, 143, 452-460.	0.4	31
116	Serum IgG and risk of exacerbations and hospitalizations in chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 2017, 140, 1164-1167.e6.	1.5	31
117	Network-based analysis reveals novel gene signatures in peripheral blood of patients with chronic obstructive pulmonary disease. Respiratory Research, 2017, 18, 72.	1.4	31
118	Serum IgG subclass levels and risk of exacerbations and hospitalizations in patients with COPD. Respiratory Research, 2018, 19, 30.	1.4	31
119	Longitudinal study of surrogate aging measures during human immunodeficiency virus seroconversion. Aging, 2017, 9, 687-705.	1.4	31
120	Genetic regulation of gene expression in the lung identifies <i>CST3</i> and <i>CD22</i> as potential causal genes for airflow obstruction. Thorax, 2014, 69, 997-1004.	2.7	30
121	Plasma pro-surfactant protein B and lung function decline in smokers. European Respiratory Journal, 2015, 45, 1037-1045.	3.1	30
122	CTS position statement: Pharmacotherapy in patients with COPD—An update. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2017, 1, 222-241.	0.2	30
123	Surfactant Protein D and Bronchial Dysplasia in Smokers at High Risk of Lung Cancer. Chest, 2008, 134, 582-588.	0.4	29
124	Whole Exome Re-Sequencing Implicates CCDC38 and Cilia Structure and Function in Resistance to Smoking Related Airflow Obstruction. PLoS Genetics, 2014, 10, e1004314.	1.5	29
125	Association of Plasma Adipokines with Chronic Obstructive Pulmonary Disease Severity and Progression. Annals of the American Thoracic Society, 2015, 12, 1005-1012.	1.5	29
126	A Randomized Phase IIb Trial of <i>myo</i> -Inositol in Smokers with Bronchial Dysplasia. Cancer Prevention Research, 2016, 9, 906-914.	0.7	29

#	Article	IF	CITATIONS
127	Hedgehog signaling in the airway epithelium of patients with chronic obstructive pulmonary disease. Scientific Reports, 2019, 9, 3353.	1.6	29
128	Phenotypic and functional translation of IL33 genetics in asthma. Journal of Allergy and Clinical Immunology, 2021, 147, 144-157.	1.5	29
129	High eosinophil counts predict decline in FEV ₁ : results from the CanCOLD study. European Respiratory Journal, 2021, 57, 2000838.	3.1	29
130	Aging does not Enhance Experimental Cigarette Smoke-Induced COPD in the Mouse. PLoS ONE, 2013, 8, e71410.	1.1	28
131	Airway Epithelial Expression Quantitative Trait Loci Reveal Genes Underlying Asthma and Other Airway Diseases. American Journal of Respiratory Cell and Molecular Biology, 2016, 54, 177-187.	1.4	28
132	Integrative Genomics of Emphysema-Associated Genes Reveals Potential Disease Biomarkers. American Journal of Respiratory Cell and Molecular Biology, 2017, 57, 411-418.	1.4	28
133	Genome-Wide Association Study Identification of Novel Loci Associated with Airway Responsiveness in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 226-234.	1.4	27
134	Serum Bilirubin and Disease Progression in Mild COPD. Chest, 2015, 148, 169-175.	0.4	27
135	Responsiveness to Ipratropium Bromide in Male and Female Patients with Mild to Moderate Chronic Obstructive Pulmonary Disease. EBioMedicine, 2017, 19, 139-145.	2.7	27
136	Long-Term Trajectories of Mild Asthma in Adulthood and Risk Factors of Progression. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 2024-2032.e5.	2.0	27
137	Economic burden of multimorbidity in patients with severe asthma: a 20-year population-based study. Thorax, 2019, 74, 1113-1119.	2.7	27
138	The Burden of Image Based Emphysema and Bronchiolitis in HIV-Infected Individuals on Antiretroviral Therapy. PLoS ONE, 2014, 9, e109027.	1.1	27
139	Longer Telomere Length in COPD Patients with α1-Antitrypsin Deficiency Independent of Lung Function. PLoS ONE, 2014, 9, e95600.	1.1	26
140	Do inhaled corticosteroids protect against lung cancer in patients with COPD? A systematic review. Respirology, 2017, 22, 61-70.	1.3	25
141	Asthma-COPD Overlap Syndrome: What We Know and What We Don't. Tuberculosis and Respiratory Diseases, 2017, 80, 11.	0.7	24
142	Asthma-COPD Overlap and Chronic Airflow Obstruction: Definitions, Management, and Unanswered Questions. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 483-495.	2.0	24
143	Macrophages with reduced expressions of classical M1 and M2 surface markers in human bronchoalveolar lavage fluid exhibit pro-inflammatory gene signatures. Scientific Reports, 2021, 11, 8282.	1.6	24
144	Ambient Air Pollution and Dysanapsis: Associations with Lung Function and Chronic Obstructive Pulmonary Disease in the Canadian Cohort Obstructive Lung Disease Study. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 44-55.	2.5	24

#	Article	IF	CITATIONS
145	Cigarette Smoking and Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 2783-2797.	2.0	24
146	Quality Assurance of Spirometry in a Population-Based Study –Predictors of Good Outcome in Spirometry Testing. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2014, 11, 143-151.	0.7	23
147	Association of blood eosinophils and plasma periostin with FEV1 response after 3-month inhaled corticosteroid and long-acting beta2-agonist treatment in stable COPD patients. International Journal of COPD, 2016, 11, 23.	0.9	23
148	Polymorphisms Associated with Expression of BPIFA1/BPIFB1 and Lung Disease Severity in Cystic Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2015, 53, 607-614.	1.4	23
149	Favorable longitudinal change of lung function in patients with asthma-COPD overlap from a COPD cohort. Respiratory Research, 2018, 19, 36.	1.4	23
150	COVID-19 in COPD: A growing concern. EClinicalMedicine, 2020, 26, 100546.	3.2	23
151	The relationship betweenHelicobacter pyloriseropositivity and COPD. Thorax, 2015, 70, 923-929.	2.7	22
152	A Systematic Review of Health Economics Simulation Models of Chronic Obstructive Pulmonary Disease. Value in Health, 2017, 20, 152-162.	0.1	22
153	Serum IgG Levels and Risk of COPD Hospitalization. Chest, 2020, 158, 1420-1430.	0.4	22
154	Asthma-COPD Overlap. Chest, 2022, 161, 330-344.	0.4	22
155	Blood and sputum protein biomarkers for chronic obstructive pulmonary disease (COPD). Expert Review of Proteomics, 2018, 15, 923-935.	1.3	21
156	Predicting Severe Chronic Obstructive Pulmonary Disease Exacerbations. Developing a Population Surveillance Approach with Administrative Data. Annals of the American Thoracic Society, 2020, 17, 1069-1076.	1.5	21
157	Should the number of acute exacerbations in the previous year be used to guide treatments in COPD?. European Respiratory Journal, 2021, 57, 2002122.	3.1	21
158	Reply to: "Current smoking is not associated with COVID-19― European Respiratory Journal, 2020, 55, 2001340.	3.1	20
159	Phenotyping airway disease with optical coherence tomography. Respirology, 2011, 16, 34-43.	1.3	19
160	What to Do When a Smoker's CT Scan Is "Normal�. Chest, 2012, 141, 1147-1152.	0.4	19
161	Budesonide/Formoterol Enhances the Expression of Pro Surfactant Protein-B in Lungs of COPD Patients. PLoS ONE, 2013, 8, e83881.	1.1	19
162	Plasma sCD14 as a Biomarker to Predict Pulmonary Exacerbations in Cystic Fibrosis. PLoS ONE, 2014, 9, e89341.	1.1	19

#	Article	IF	CITATIONS
163	Gender differences in first and secondhand smoke exposure, spirometric lung function and cardiometabolic health in the old order Amish: A novel population without female smoking. PLoS ONE, 2017, 12, e0174354.	1.1	19
164	Occurrence of Accelerated Epigenetic Aging and Methylation Disruptions in Human Immunodeficiency Virus Infection Before Antiretroviral Therapy. Journal of Infectious Diseases, 2021, 223, 1681-1689.	1.9	19
165	Meta-analysis of exome array data identifies six novel genetic loci for lung function. Wellcome Open Research, 2018, 3, 4.	0.9	19
166	COPD Exacerbation Biomarkers Validated Using Multiple Reaction Monitoring Mass Spectrometry. PLoS ONE, 2016, 11, e0161129.	1.1	19
167	Impaired Ventilatory Efficiency, Dyspnea, and Exercise Intolerance in Chronic Obstructive Pulmonary Disease: Results from the CanCOLD Study. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1391-1402.	2.5	19
168	Is COPD Really a Cardiovascular Disease?. Chest, 2009, 136, 329-330.	0.4	18
169	Susceptibility loci for lung cancer are associated with mRNA levels of nearby genes in the lung. Carcinogenesis, 2014, 35, 2653-2659.	1.3	18
170	Effect of controlled human exposure to diesel exhaust and allergen on airway surfactant protein D, myeloperoxidase and club (Clara) cell secretory protein 16. Clinical and Experimental Allergy, 2016, 46, 1206-1213.	1.4	18
171	The Effect of Different Case Definitions of Current Smoking on the Discovery of Smoking-Related Blood Gene Expression Signatures in Chronic Obstructive Pulmonary Disease. Nicotine and Tobacco Research, 2016, 18, 1903-1909.	1.4	18
172	Inhaled corticosteroids in COPD: the final verdict is…. European Respiratory Journal, 2018, 52, 1801940.	3.1	18
173	Relationship of Absolute Telomere Length With Quality of Life, Exacerbations, and Mortality in COPD. Chest, 2018, 154, 266-273.	0.4	18
174	The Overlap of Lung Tissue Transcriptome of Smoke Exposed Mice with Human Smoking and COPD. Scientific Reports, 2018, 8, 11881.	1.6	18
175	Simulation of nanoparticle transport and adsorption in a microfluidic lung-on-a-chip device. Biomicrofluidics, 2020, 14, 044117.	1.2	18
176	Protective effect of club cell secretory protein (CC-16) on COPD risk and progression: a Mendelian randomisation study. Thorax, 2020, 75, 934-943.	2.7	17
177	<p>The Long-Term Burden of COPD Exacerbations During Maintenance Therapy and Lung Function Decline</p> . International Journal of COPD, 2020, Volume 15, 1909-1918.	0.9	17
178	Association of Forced Vital Capacity with the Developmental Gene NCOR2. PLoS ONE, 2016, 11, e0147388.	1.1	17
179	The molecular and cellular mechanisms associated with the destruction of terminal bronchioles in COPD. European Respiratory Journal, 2022, 59, 2101411.	3.1	17
180	Can inhaled fluticasone alone or in combination with salmeterol reduce systemic inflammation in chronic obstructive pulmonary disease? – study protocol for a randomized controlled trial [NCT00120978]. BMC Pulmonary Medicine, 2006, 6, 3.	0.8	16

#	Article	IF	CITATIONS
181	Biomarkers of Therapeutic Response in Patients with Chronic Obstructive Pulmonary Disease. Drugs, 2011, 71, 1821-1837.	4.9	16
182	The Effect of Statins on Blood Gene Expression in COPD. PLoS ONE, 2015, 10, e0140022.	1.1	16
183	Ectopic adiposity and cardiometabolic health in COPD. International Journal of COPD, 2018, Volume 13, 3331-3340.	0.9	16
184	Phenotyping COPD exacerbations using imaging and blood-based biomarkers. International Journal of COPD, 2018, Volume 13, 217-229.	0.9	16
185	<p>Trends in prescriptions and costs of inhaled medications in chronic obstructive pulmonary disease: a 19-year population-based study from Canada</p> . International Journal of COPD, 2019, Volume 14, 2003-2013.	0.9	16
186	Biomarkers in Chronic Obstructive Pulmonary Disease. Clinics in Chest Medicine, 2020, 41, 383-394.	0.8	16
187	Sex differences in lymphoid follicles in COPD airways. Respiratory Research, 2020, 21, 46.	1.4	16
188	The Prevalence of Chronic Obstructive Pulmonary Disease (COPD) and the Heterogeneity of Risk Factors in the Canadian Population: Results from the Canadian Obstructive Lung Disease (COLD) Study. International Journal of COPD, 2021, Volume 16, 305-320.	0.9	16
189	Emphysema in an adult with galactosialidosis linked to a defect in primary elastic fiber assembly. Molecular Genetics and Metabolism, 2012, 106, 99-103.	0.5	15
190	Lung expression quantitative trait loci data setÂidentifies important functional polymorphisms in the asthma-associated IL1RL1 region. Journal of Allergy and Clinical Immunology, 2014, 134, 729-731.	1.5	15
191	Surfactant protein-D deficiency suppresses systemic inflammation and reduces atherosclerosis in ApoE knockout mice. Cardiovascular Research, 2017, 113, 1208-1218.	1.8	15
192	A Potent Tartrate Resistant Acid Phosphatase Inhibitor to Study the Function of TRAP in Alveolar Macrophages. Scientific Reports, 2017, 7, 12570.	1.6	15
193	An Individualized Prediction Model for Long-term Lung Function Trajectory and Risk of COPD in the General Population. Chest, 2020, 157, 547-557.	0.4	15
194	Aryl hydrocarbon receptor deficiency causes the development of chronic obstructive pulmonary disease through the integration of multiple pathogenic mechanisms. FASEB Journal, 2021, 35, e21376.	0.2	15
195	Development of a Blood-based Transcriptional Risk Score for Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 161-170.	2.5	15
196	Deficiency of <scp>FHL</scp> 2 attenuates airway inflammation in mice and genetic variation associates with human bronchial hyperâ€responsiveness. Allergy: European Journal of Allergy and Clinical Immunology, 2015, 70, 1531-1544.	2.7	14
197	Recurrent pneumothorax related to diffuse dendriform pulmonary ossification in genetically predisposed individual. Respirology Case Reports, 2017, 5, e00211.	0.3	14
198	The pharmacogenomics of inhaled corticosteroids and lung function decline in COPD. European Respiratory Journal, 2019, 54, 1900521.	3.1	14

#	Article	IF	CITATIONS
199	Accelerated lung aging and chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2019, 13, 369-380.	1.0	14
200	Effects of sex and chronic cigarette smoke exposure on the mouse cecal microbiome. PLoS ONE, 2020, 15, e0230932.	1.1	14
201	C-reactive protein and N-terminal prohormone brain natriuretic peptide as biomarkers in acute exacerbations of COPD leading to hospitalizations. PLoS ONE, 2017, 12, e0174063.	1.1	14
202	Airway luminal area and the resistive work of breathing during exercise in healthy young females and males. Journal of Applied Physiology, 2021, 131, 1750-1761.	1.2	14
203	SABRE: a method for assessing the stability of gene modules in complex tissues and subject populations. BMC Bioinformatics, 2016, 17, 460.	1.2	13
204	Abundance of Non-Polarized Lung Macrophages with Poor Phagocytic Function in Chronic Obstructive Pulmonary Disease (COPD). Biomedicines, 2020, 8, 398.	1.4	13
205	The Relation of Serum Myeloperoxidase to Disease Progression and Mortality in Patients with Chronic Obstructive Pulmonary Disease (COPD). PLoS ONE, 2013, 8, e61315.	1.1	13
206	Thinning Bone and Inhaled Corticosteroid in COPD. Chest, 2009, 136, 1448-1449.	0.4	12
207	Independent association of subclinical coronary artery disease and emphysema in <scp>HIV</scp> â€infected patients. HIV Medicine, 2016, 17, 178-187.	1.0	12
208	Susceptibility genes for lung diseases in the major histocompatibility complex revealed by lung expression quantitative trait loci analysis. European Respiratory Journal, 2016, 48, 573-576.	3.1	12
209	Targeted high-throughput sequencing of candidate genes for chronic obstructive pulmonary disease. BMC Pulmonary Medicine, 2016, 16, 146.	0.8	12
210	Proteomic Profiling to Identify Blood Biomarkers Predictive of Response to Azithromycin in Children and Adolescents With Cystic Fibrosis. Chest, 2019, 156, 667-673.	0.4	12
211	Karma of Cardiovascular Disease Risk Factors for Prevention and Management of Major Cardiovascular Events in the Context of Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Frontiers in Cardiovascular Medicine, 2019, 6, 79.	1.1	12
212	Widespread Sexual Dimorphism in the Transcriptome of Human Airway Epithelium in Response to Smoking. Scientific Reports, 2019, 9, 17600.	1.6	12
213	Particle depletion of diesel exhaust restores allergen-induced lung-protective surfactant protein D in human lungs. Thorax, 2020, 75, 640-647.	2.7	12
214	ACE inhibition and cardiometabolic risk factors, lung <i>ACE2</i> and <i>TMPRSS2</i> gene expression, and plasma ACE2 levels: a Mendelian randomization study. Royal Society Open Science, 2020, 7, 200958.	1.1	12
215	DNA methylation is associated with airflow obstruction in patients living with HIV. Thorax, 2021, 76, 448-455.	2.7	12
216	COPD and cardiovascular diseases: now is the time for action!. Thorax, 2018, 73, 799-800.	2.7	11

#	Article	IF	CITATIONS
217	Chronic Obstructive Pulmonary Disease as a Risk Factor for Cardiovascular Disease. A View from the SUMMIT. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 2-4.	2.5	11
218	Severity of Airflow Obstruction and Work Loss in a Nationwide Population of Working Age. Scientific Reports, 2018, 8, 9674.	1.6	11
219	The genetics of smoking in individuals with chronic obstructive pulmonary disease. Respiratory Research, 2018, 19, 59.	1.4	11
220	Current Controversies in Chronic Obstructive Pulmonary Disease. A Report from the Global Initiative for Chronic Obstructive Lung Disease Scientific Committee. Annals of the American Thoracic Society, 2019, 16, 29-39.	1.5	11
221	Microchip RT-PCR Detection of Nasopharyngeal SARS-CoV-2 Samples. Journal of Molecular Diagnostics, 2021, 23, 683-690.	1.2	11
222	Meta-analysis of exome array data identifies six novel genetic loci for lung function. Wellcome Open Research, 0, 3, 4.	0.9	11
223	SP-D Polymorphisms and the Risk of COPD. Disease Markers, 2012, 33, 91-100.	0.6	10
224	The devastating power of platelets in COPD exacerbations: can aspirin save lives in COPD?. Thorax, 2014, 69, 603-604.	2.7	10
225	Lung and Heart Diseases Are Better Predicted by Pack-Years than by Smoking Status or Duration of Smoking Cessation in HIV Patients. PLoS ONE, 2015, 10, e0143700.	1.1	10
226	Development and Validation of the Evaluation Platform in COPD (EPIC): A Population-Based Outcomes Model of COPD for Canada. Medical Decision Making, 2019, 39, 152-167.	1.2	10
227	Unifying thoracic biomarkers: surfactant protein-D and beyond. Expert Review of Respiratory Medicine, 2012, 6, 147-154.	1.0	9
228	Sulfatase modifying factor 1 (SUMF1) is associated with Chronic Obstructive Pulmonary Disease. Respiratory Research, 2017, 18, 77.	1.4	9
229	The role of beta-blockers in the management of chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine, 2018, 12, 125-135.	1.0	9
230	Multiple reaction monitoring mass spectrometry to identify novel plasma protein biomarkers of treatment response in cystic fibrosis pulmonary exacerbations. Journal of Cystic Fibrosis, 2018, 17, 333-340.	0.3	9
231	Blood biomarkers to predict short-term pulmonary exacerbation risk in children and adolescents with CF: A pilot study. Journal of Cystic Fibrosis, 2020, 19, 49-51.	0.3	9
232	SARS-CoV-2 rapid antigen testing for departing passengers at Vancouver International Airport. Journal of Travel Medicine, 2021, 28, .	1.4	9
233	Confronting the Colossal Crisis of COPD in China. Chest, 2011, 139, 735-736.	0.4	8
234	The bronchial epithelial cell bacterial microbiome and host response in patients infected with human immunodeficiency virus. BMC Pulmonary Medicine, 2016, 16, 142.	0.8	8

#	Article	IF	CITATIONS
235	Differential lung tissue gene expression in males and females: implications for the susceptibility to develop COPD. European Respiratory Journal, 2019, 54, 1702567.	3.1	8
236	Computed Tomography Vascular Tree-in-Bud: A Novel Prognostic Imaging Biomarker in COVID-19?. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 642-644.	2.5	8
237	Inhaled Corticosteroids Selectively Alter the Microbiome and Host Transcriptome in the Small Airways of Patients with Chronic Obstructive Pulmonary Disease. Biomedicines, 2022, 10, 1110.	1.4	8
238	Why are women more vulnerable to chronic obstructive pulmonary disease?. Expert Review of Respiratory Medicine, 2013, 7, 197-199.	1.0	7
239	Enumerateblood – an R package to estimate the cellular composition of whole blood from Affymetrix Gene ST gene expression profiles. BMC Genomics, 2017, 18, 43.	1.2	7
240	<p>Phenotyping and outcomes of hospitalized COPD patients using rapid molecular diagnostics on sputum samples</p> . International Journal of COPD, 2019, Volume 14, 311-319.	0.9	7
241	Inhaled corticosteroids and fractures in chronic obstructive pulmonary disease. Current Opinion in Pulmonary Medicine, 2019, 25, 165-172.	1.2	7
242	Various factors affect lipopolysaccharide sensitization in cell cultures. BioTechniques, 2020, 69, 126-132.	0.8	7
243	Dyspnoea and symptom burden in mild–moderate COPD: the Canadian Cohort Obstructive Lung Disease Study. ERJ Open Research, 2021, 7, 00960-2020.	1.1	7
244	FAM13A as potential therapeutic target in modulating TGF-β-induced airway tissue remodeling in COPD. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2021, 321, L377-L391.	1.3	7
245	Crisis of COPD in China: the future is now. Lancet Respiratory Medicine, the, 2018, 6, 404-405.	5.2	6
246	Precision health: treating the individual patient with chronic obstructive pulmonary disease. Medical Journal of Australia, 2019, 210, 424-428.	0.8	6
247	The Role of Granzyme B Containing Cells in the Progression of Chronic Obstructive Pulmonary Disease. Tuberculosis and Respiratory Diseases, 2020, 83, S25-S33.	0.7	6
248	Epigenetic marker of telomeric age is associated with exacerbations and hospitalizations in chronic obstructive pulmonary disease. Respiratory Research, 2021, 22, 316.	1.4	6
249	GETting to know the many causes and faces of COPD. Lancet Respiratory Medicine,the, 2022, 10, 426-428.	5.2	6
250	The impact of IgG subclass deficiency on the risk of mortality in hospitalized patients with COPD. Respiratory Research, 2022, 23, .	1.4	6
251	COPD in never smokers: prognosis unveiled. Lancet Respiratory Medicine,the, 2013, 1, 502-504.	5.2	5
252	Wanted: new treatments for COPD. Lancet Respiratory Medicine, the, 2014, 2, 434-436.	5.2	5

#	Article	IF	CITATIONS
253	Impact of individualized care on readmissions after a hospitalization for acute exacerbation of COPD. International Journal of COPD, 2016, 11, 61.	0.9	5
254	Should We Screen for Pulmonary Embolism in Severe COPD Exacerbations? Not JustÂYet, Primum Non Nocere. Chest, 2017, 151, 523-524.	0.4	5
255	What are the long-term effects of smoked marijuana on lung health?. Cmaj, 2018, 190, E1243-E1244.	0.9	5
256	Twentyâ€five years of <i>Respirology</i> : Advances in COPD. Respirology, 2020, 25, 17-19.	1.3	5
257	Healthcare system encounters before COPD diagnosis: a registry-based longitudinal cohort study. Thorax, 2020, 75, 108-115.	2.7	5
258	IgG Levels and Mortality in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine, 2021, 204, 362-365.	2.5	5
259	Epigenetic blood biomarkers of ageing and mortality in COPD. European Respiratory Journal, 2021, 58, 2101890.	3.1	5
260	Vascular and renal telomere shortening in mice exposed to chronic intermittent hypoxia. Canadian Journal of Physiology and Pharmacology, 2021, 99, 1112-1113.	0.7	5
261	Long-acting beta2-agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease. The Cochrane Library, 2014, ,	1.5	4
262	Impact of Statins on Gene Expression in Human Lung Tissues. PLoS ONE, 2015, 10, e0142037.	1.1	4
263	Current methods to diagnose small airway disease in patients with COPD. Expert Review of Respiratory Medicine, 2016, 10, 417-429.	1.0	4
264	Chronic Obstructive Pulmonary Disease and Stroke. Strange Bedfellows. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 227-228.	2.5	4
265	COPD in China. Chest, 2018, 154, 474-475.	0.4	4
266	Effect of short-term oral prednisone therapy on blood gene expression: a randomised controlled clinical trial. Respiratory Research, 2019, 20, 176.	1.4	4
267	Understanding racial differences of COPD patients with an ecological model: two large cohort studies in the US and Korea. Therapeutic Advances in Chronic Disease, 2021, 12, 204062232098245.	1.1	4
268	Variants associated with HHIP expression have sex-differential effects on lung function. Wellcome Open Research, 2020, 5, 111.	0.9	4
269	Smoking kills, quitting heals: the importance of smoking cessation in COPD. Clinical Respiratory Journal, 2011, 5, 185-186.	0.6	3
270	COPD: Lessons learned, forging a fantastic future. Respirology, 2017, 22, 632-633.	1.3	3

#	Article	IF	CITATIONS
271	Azithromycin and risk of COPD exacerbations in patients with and without Helicobacter pylori. Respiratory Research, 2017, 18, 109.	1.4	3
272	Inhaled Corticosteroids and Fractures in COPD. Chest, 2018, 153, 293-294.	0.4	3
273	Relative impact characteristic curve: a graphical tool to visualize and quantify the clinical utility and population-level consequences of implementing markers. Annals of Epidemiology, 2018, 28, 717-723.e3.	0.9	3
274	Gender modifies the effect of body mass index on lung function decline in mild-to-moderate COPD patients: a pooled analysis. Respiratory Research, 2021, 22, 59.	1.4	3
275	Mild catalytic defects of tert rs61748181 polymorphism affect the clinical presentation of chronic obstructive pulmonary disease. Scientific Reports, 2021, 11, 4333.	1.6	3
276	Variants associated with HHIP expression have sex-differential effects on lung function. Wellcome Open Research, 2020, 5, 111.	0.9	3
277	Methylxanthines in COPD: yes to caffeine, no to theophylline. European Respiratory Journal, 2021, 57, 2004564.	3.1	3
278	Clotting in COVID-19: Is It All in the Genes?. American Journal of Respiratory Cell and Molecular Biology, 2021, 64, 647-649.	1.4	3
279	Association of surfactant protein D with pulmonary metastases from colon cancer. Oncology Letters, 2020, 20, 322.	0.8	3
280	Recruitment for a provincial asthma study. Participation of network and non-network primary care physicians. Canadian Family Physician, 2004, 50, 1251-4.	0.1	3
281	Airway Eosinophilia on Bronchoalveolar Lavage and the Risk of Exacerbations in COPD. Biomedicines, 2022, 10, 1412.	1.4	3
282	Smoke and Mirrors. Chest, 2014, 146, 875-876.	0.4	2
283	Should COPD stand for "comorbidity-related obstructive pulmonary disease�. European Respiratory Journal, 2015, 46, 901-902.	3.1	2
284	Concern of underdiagnosing asthma–COPD overlap syndrome if age limit of 40â€years for asthma is used. European Respiratory Journal, 2017, 50, 1701120.	3.1	2
285	The Impact of Care Specialty on Survival-Adjusted Medical Costs of COPD Patients After a Hospitalization: a longitudinal analysis. Journal of General Internal Medicine, 2018, 33, 1528-1535.	1.3	2
286	External radiofrequency as a novel extracorporeal therapy for emphysema. European Respiratory Journal, 2020, 56, 2001422.	3.1	2
287	Vitamin D Deficiency in COPD. Chest, 2020, 157, 755-756.	0.4	2
288	Olodaterol exerts anti-inflammatory effects on COPD airway epithelial cells. Respiratory Research, 2021, 22, 65.	1.4	2

#	Article	IF	CITATIONS
289	Predictors of emphysema progression in HIV-positive patients. Journal of the International AIDS Society, 2014, 17, 19660.	1.2	1
290	COPD. Chest, 2015, 147, 868-869.	0.4	1
291	Unravelling the many faces of chronic obstructive pulmonary disease: A hitchhiker's guide to <scp>COPD</scp> . Respirology, 2016, 21, 12-13.	1.3	1
292	Reply. Journal of Allergy and Clinical Immunology, 2018, 141, 831.	1.5	1
293	What triggers acute exacerbations of COPD? Why not ask the patient!. Respirology, 2019, 24, 7-8.	1.3	1
294	Contemporary Concise Review 2019: Chronic obstructive pulmonary disease. Respirology, 2020, 25, 449-454.	1.3	1
295	Meta-analysis of exome array data identifies six novel genetic loci for lung function. Wellcome Open Research, 0, 3, 4.	0.9	1
296	Radiofrequency therapy improves exercise capacity of mice with emphysema. Scientific Reports, 2021, 11, 20056.	1.6	1
297	Associations of interleukin-1 gene cluster polymorphisms with C-reactive protein concentration and lung function decline in smoking-induced chronic obstructive pulmonary disease. International Journal of Clinical and Experimental Pathology, 2015, 8, 13125-35.	0.5	1
298	Ketogenic diet for mitochondrial disease: potential role in treating the Multiple Symmetric Lipomatosis phenotype associated with the common MT-TK genetic mutation. Orphanet Journal of Rare Diseases, 2022, 17, 12.	1.2	1
299	Therapeutic options for chronic obstructive pulmonary disease: present and future. European Review for Medical and Pharmacological Sciences, 2004, 8, 247-58.	0.5	1
300	Combination of ICSs and LABAs Should Be Used in the Management of Patients with COPD The Pro Argument. Canadian Respiratory Journal, 2004, 11, 221-223.	0.8	0
301	In reply to â€~Geographic variability in COPD prevalence' [Correspondence]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 710-710.	0.6	0
302	Response. Chest, 2017, 152, 221-222.	0.4	0
303	GDF11: a fountain of youth for the ageing COPD lung?. Thorax, 2017, 72, 874-875.	2.7	0
304	Long-acting beta ₂ -agonists and long-acting muscarinic antagonists in a combined inhaler versus either agent alone or placebo for chronic obstructive pulmonary disease. The Cochrane Library, 0, , .	1.5	0
305	Imaging End Points in COPD Clinical Trials. Chest, 2018, 154, 3-5.	0.4	0
306	Precision health in COPD: Now is the time. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2018, 2, 128-132.	0.2	0

#	Article	IF	CITATIONS
307	Is COPD management getting better or worse? How would we know without benchmarking?. Canadian Journal of Respiratory, Critical Care, and Sleep Medicine, 2019, 3, 28-29.	0.2	0
308	Blood biomarkers in chronic obstructive pulmonary disease: is there a life beyond plasma fibrinogen?. International Journal of Tuberculosis and Lung Disease, 2019, 23, 963-964.	0.6	0
309	What's in the CART? A decision rule to predict shortâ€ŧerm mortality during COPD exacerbations. Respirology, 2019, 24, 716-717.	1.3	0
310	A letter from â€~O Canada'. Respirology, 2019, 24, 186-187.	1.3	0
311	Response. Chest, 2020, 157, 738-739.	0.4	0
312	Impact of marijuana smoking on lung function in older persons. European Respiratory Journal, 2020, 55, 1902390.	3.1	0
313	IL-4Rα blockade reduces influenza-associated morbidity in a murine model of allergic asthma. Respiratory Research, 2021, 22, 75.	1.4	0
314	A mechanical test of the tenertaxis hypothesis for leukocyte diapedesis. European Physical Journal E, 2021, 44, 93.	0.7	0
315	Disease activity in COPD: time to make imaging biomarkers a PET project?. ERJ Open Research, 2021, 7, 00445-2021.	1.1	0
316	The role of MMP2 in persistent inflammation in Chronic Obstructive Pulmonary Disease (COPD). FASEB Journal, 2009, 23, 572.13.	0.2	0
017	software development TO OPTIMIZE THE minimal detectable difference IN huMAN AIRWAY IMAGES	0.5	0

017	software development to of minize the minimal detectable difference in numAn AikwAt miAoes		
31/	CAPTURED USING optical coherence tomography. Clinical Physiology and Functional Imaging, 2022, , .	0.5	U
	CAPTURED USING ODLICAL CONFERICE LOMOGRADIV. CILINICAL PRIVSIOLOGY AND FUNCTIONAL IMAGING, 2022,		